{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:26:49Z","timestamp":1789165609866,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    The momentum of gene therapy in Huntington's disease (HD) deserves biomarkers from easily accessible fluid. We planned a study to verify whether plasma miRNome may provide useful peripheral \u201creporter(s)\u201d for the management of HD patients. We performed an exploratory microarray study of whole non-coding RNA profiles in plasma from nine patients with HD and 13 matched controls [eight healthy subjects (HS) and five psychiatric patients (PP) to minimize possible iatrogenic impact on the profile of non-coding RNAs]. We found an HD-specific signature: downregulation of hsa-miR-98 (fold change, \u22121.5,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0338 HD vs. HS, and fold change, 1.5,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0045 HD vs. PP) and upregulation of hsa-miR-323b-3p (fold change, 1.5,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0007 HD vs. HS, and fold change, 1.5,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0111 HD vs. PP). To validate this result in an independent cohort, we quantify by digital droplet PCR (ddPCR) the presence of the two microRNA in the plasma of 33 HD patients and 49 matched controls (25 HS and 24 PP patients). We were able to confirm that hsa-miR-323b-3p was upregulated in HD and premanifest HD vs. HS and PP: the median values (first\u2013third quartile) were 4.1 (0.9\u201310.53) and 5.8 (1.9\u201310.70) vs. 0.69 (0.3\u20132.75) and 1.4 (0.78\u20132.70), respectively,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.05. No significant difference was found for hsa-miR-98. To evaluate the biological plausibility of the hsa-miR-323b-3p as a component of the disease pathophysiology, we performed a bioinformatic analysis based on its targetome and the huntingtin (HTT) interactome. We found a statistically significant overconnectivity between the targetome of hsa-miR-323b-3p and the HTT interactome (\n                    <jats:italic>p<\/jats:italic>\n                    = 1.48e\u221208). Furthermore, there was a significant transcription regulation of the HTT interactome by the miR-323b-3p targetome (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.02). The availability of handy, reproducible, and minimally invasive biomarkers coming from peripheral miRNome may be valuable to characterize the illness progression, to indicate new therapeutic targets, and to monitor the effect of disease-modifying treatments. Our data deserve further studies with larger sample size and longitudinal design.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2021.657973","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T02:04:49Z","timestamp":1620180289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Michela","family":"Ferraldeschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Morena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Mechelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ubaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Buscarinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Umeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ristori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/jnnp-2013-305114","article-title":"PREDICT HD investigators and Coordinators of the Huntington Study Group. Cognitive decline in prodromal Huntington Disease: implications for clinical trials","volume":"84","author":"Paulsen","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage disease in the TRACK-HD study: analysis of 36-month observation data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/brain\/awv214","article-title":"Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington's Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/brain\/awn212","article-title":"Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease","volume":"131","author":"Leoni","year":"2008","journal-title":"Brain."},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nbd.2013.03.013","article-title":"The members of the PREDICT-HD study group. Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression","volume":"55","author":"Leoni","year":"2013","journal-title":"Neurobiol Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1084\/jem.20160776","article-title":"Potential biomarkers to follow the progression and treatment response of Huntington's disease","volume":"213","author":"Disatnik","year":"2016","journal-title":"J Exp Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Nfl protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","article-title":"Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis","volume":"19","author":"Scahill","year":"2020","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1172\/JCI64565","article-title":"Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression","volume":"122","author":"Weiss","year":"2012","journal-title":"J Clin Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/ejhg.2014.281","article-title":"Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood","volume":"23","author":"Mastrokolias","year":"2015","journal-title":"Eur J Hum Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jns.2018.10.024","article-title":"Leukocyte telomere shortening in Huntington's disease","volume":"396","author":"Scarabino","year":"2019","journal-title":"J Neurol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.25393","article-title":"DNA damage signatures in peripheral blood cells as biomarkers in prodromal Huntington disease","volume":"84","author":"Castaldo","year":"2019","journal-title":"Ann Neurol."},{"key":"B15","first-page":"673","article-title":"MicroRNAs: target recognition and regulatory function","volume":"138","author":"Bartel","year":"2009","journal-title":"Cell."},{"key":"B16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bcp.2017.07.008","article-title":"MicroRNA: basic concepts and implication for regeneration and repair of neurodegenerative disease","volume":"141","author":"Saraiva","year":"2017","journal-title":"Biochem Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1523\/JNEUROSCI.2390-08.2008","article-title":"The bifunctional microRNA miR-9\/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease","volume":"28","author":"Packer","year":"2008","journal-title":"J Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12920-015-0083-3","article-title":"miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement","volume":"8","author":"Hoss","year":"2015","journal-title":"BMC Med Genomics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.nbd.2007.11.001","article-title":"A microRNA-based gene dysregulation pathway in Huntington's disease","volume":"29","author":"Johnson","year":"2008","journal-title":"Neurobiol Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/mds.26457","article-title":"Study of plasma-derived miRNAs mimic differences in Huntington's disease brain","volume":"30","author":"Hoss","year":"2015","journal-title":"Mov Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12017-012-8183-0","article-title":"Mechanism(s) of alteration of micro RNA expressions in huntington's disease and their possible contributions to the observed cellular and molecular dysfunctions in the disease","volume":"14","author":"Sinha","year":"2012","journal-title":"Neuromolecular Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fnmol.2019.00156","article-title":"The emerging role of microRNAs in polyglutamine diseases","volume":"12","author":"Dong","year":"2019","journal-title":"Front Mol Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.celrep.2018.07.017","article-title":"Huntingtin aggregation impairs autophagy, leading to argonaute-2 accumulation and global MicroRNA dysregulation","volume":"24","author":"Pircs","year":"2018","journal-title":"Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1212\/WNL.0000000000004844","article-title":"MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study, PREDICT-HD CSF ancillary study investigators","volume":"90","author":"Reed","year":"2018","journal-title":"Neurology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13023-017-0742-x","article-title":"Down-regulation of miR-9* in the peripheral leukocytes of Huntington's disease patients","volume":"12","author":"Chang","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2016.05.005","article-title":"Circulating microRNAs in Huntington's disease: emerging mediators in metabolic impairment","volume":"108","author":"D\u00edez-Planelles","year":"2016","journal-title":"Pharmacol Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1093\/hmg\/ddr111","article-title":"Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease","volume":"20","author":"Gaughwin","year":"2011","journal-title":"Hum Mol Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1800619","DOI":"10.1002\/mnfr.201800619","article-title":"Customized dietary intervention avoids unintentional weight loss and modulates 2018 circulating miRNAs footprint in huntington's disease","volume":"62","author":"Aganzo","year":"2018","journal-title":"Mol Nutr Food Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"D127","DOI":"10.1093\/nar\/gkz757","article-title":"miRDB:an online database for prediction of functional microRNA targets","volume":"48","author":"Yuhao","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"D529","DOI":"10.1093\/nar\/gky1079","article-title":"The BioGRID interaction database: 2019 update","volume":"47","author":"Oughtred","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00438-016-1179-y","article-title":"Characters, functions and clinical perspectives of long non-coding RNAs","volume":"291","author":"Wu","year":"2016","journal-title":"Mol Genet Genomics."},{"key":"B32","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in huntington's disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci Transl Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"J Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.657973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T02:04:53Z","timestamp":1620180293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.657973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":33,"alternative-id":["10.3389\/fneur.2021.657973"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.657973","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"article-number":"657973"}}